203 related articles for article (PubMed ID: 33926838)
1. Long-term Outcomes of Focal Cryotherapy for Low- to Intermediate-risk Prostate Cancer: Results and Matched Pair Analysis with Active Surveillance.
Marra G; Soeterik T; Oreggia D; Tourinho-Barbosa R; Moschini M; Filippini C; van Melick HHE; van den Bergh RCN; Gontero P; Cathala N; Macek P; Sanchez-Salas R; Cathelineau X
Eur Urol Focus; 2022 May; 8(3):701-709. PubMed ID: 33926838
[TBL] [Abstract][Full Text] [Related]
2. Focal High-Intensity Focused Ultrasound vs. Active Surveillance for ISUP Grade 1 Prostate Cancer: Medium-Term Results of a Matched-Pair Comparison.
Marra G; Soeterik T; Oreggia D; Tourinho-Barbosa R; Moschini M; Stabile A; Filippini C; van Melick HH; van den Bergh RC; Gontero P; Pasquali C; Macek P; Cathala N; Sanchez-Salas R; Cathelineau X
Clin Genitourin Cancer; 2022 Dec; 20(6):592-604. PubMed ID: 35918262
[TBL] [Abstract][Full Text] [Related]
3. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.
Bahn D; de Castro Abreu AL; Gill IS; Hung AJ; Silverman P; Gross ME; Lieskovsky G; Ukimura O
Eur Urol; 2012 Jul; 62(1):55-63. PubMed ID: 22445223
[TBL] [Abstract][Full Text] [Related]
4. Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance.
Whalen MJ; Pak JS; Lascano D; Ahlborn D; Matulay JT; McKiernan JM; Benson MC; Wenske S
Clin Genitourin Cancer; 2018 Apr; 16(2):e425-e435. PubMed ID: 29113772
[TBL] [Abstract][Full Text] [Related]
5. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.
Shah TT; Peters M; Eldred-Evans D; Miah S; Yap T; Faure-Walker NA; Hosking-Jervis F; Thomas B; Dudderidge T; Hindley RG; McCracken S; Greene D; Nigam R; Valerio M; Minhas S; Winkler M; Arya M; Ahmed HU
Eur Urol; 2019 Jul; 76(1):98-105. PubMed ID: 30638633
[TBL] [Abstract][Full Text] [Related]
6. Operative and Midterm Oncological Outcome of Focal Salvage Cryotherapy for Localized Prostate Cancer.
Vestris PG; Giwerc A; Hennequin C; Goujon A; Meria P; Verine J; Desgrandchamps F; de Kerviler E; Mongiat-Artus P; Masson-Lecomte A
Urol Int; 2022; 106(9):897-902. PubMed ID: 34781287
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Kellokumpu-Lehtinen PL; Hjälm-Eriksson M; Thellenberg-Karlsson C; Åström L; Franzen L; Fransson AS; Leskinen MJ; Zeke M; Huttunen T; Ginman C;
Eur Urol; 2019 Dec; 76(6):823-830. PubMed ID: 31443961
[TBL] [Abstract][Full Text] [Related]
9. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A
Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
[TBL] [Abstract][Full Text] [Related]
10. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
11. Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control.
van Son MJ; Peters M; Reddy D; Shah TT; Hosking-Jervis F; Robinson S; Lagendijk JJW; Mangar S; Dudderidge T; McCracken S; Hindley RG; Emara A; Nigam R; Persad R; Virdi J; Lewi H; Moore C; Orczyk C; Emberton M; Arya M; Ahmed HU; van der Voort van Zyp JRN; Winkler M; Falconer A
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1120-1128. PubMed ID: 33934114
[TBL] [Abstract][Full Text] [Related]
12. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
13. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
14. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
Guillaumier S; Peters M; Arya M; Afzal N; Charman S; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Shah K; van der Meulen J; Virdi J; Winkler M; Emberton M; Ahmed HU
Eur Urol; 2018 Oct; 74(4):422-429. PubMed ID: 29960750
[TBL] [Abstract][Full Text] [Related]
15. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer.
Shah TT; Peters M; Miah S; Eldred-Evans D; Yap T; Hosking-Jervis F; Dudderidge T; Hindley RG; McCracken S; Greene D; Nigam R; Valerio M; Winkler M; Virdi J; Arya M; Ahmed HU; Minhas S
Eur Urol Focus; 2021 Mar; 7(2):301-308. PubMed ID: 31590961
[TBL] [Abstract][Full Text] [Related]
17. Medium-term oncological outcomes of intermediate-risk prostate cancer treated with HIFU or cryotherapy. A single center 10-year experience.
Dias N; Rodriguez-Sanchez L; Colandrea G; Macek P; Cathelineau X
Arch Ital Urol Androl; 2022 Dec; 94(4):413-419. PubMed ID: 36576465
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
19. Comparing High-Intensity Focal Ultrasound Hemiablation to Robotic Radical Prostatectomy in the Management of Unilateral Prostate Cancer: A Matched-Pair Analysis.
Albisinni S; Aoun F; Bellucci S; Biaou I; Limani K; Hawaux E; Peltier A; van Velthoven R
J Endourol; 2017 Jan; 31(1):14-19. PubMed ID: 27799004
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience.
Habashy D; Reddy D; Peters M; Shah TT; van Son M; van Rossum PSN; Tanaka MB; Cullen E; Engle R; McCracken S; Greene D; Hindley RG; Emara A; Nigam R; Orczyk C; Shergill I; Persad R; Virdi J; Moore CM; Arya M; Winkler M; Emberton M; Ahmed HU; Dudderidge T
J Urol; 2023 Jul; 210(1):108-116. PubMed ID: 37014172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
